**Exhibit 99.1**   Contact: Joseph S. Podolski  President & CEO  (281) 719-3447**Repros Therapeutics Inc. Reports Second Quarter 2007 Financial Results**THE WOODLANDS, Texas — August 8, 2007 — Repros Therapeutics (NasdaqGM: RPRX) today announcedfinancial results for the three-month and six-month periods ended June 30, 2007.**Financial Results**     Total revenues for the three-month period ended June 30, 2007 were $442,000 as compared to$166,000 for same period in the prior year and were $759,000 for the six-month period ended June30, 2007 as compared to $340,000 for the same period in the prior year. Revenues for thethree-month and six-month periods ended June 30, 2007 consist of interest income and the increasein interest income is primarily due to an increase in marketable securities as a result of thecompletion of the Company’s follow-on public offering on February 5, 2007 in which the Companyreceived approximately $33.1 million in net proceeds.     Research and development expenses, which include contracted clinical activities, regulatoryaffairs and general research expenses increased 36% to approximately $3.2 million for thethree-month period ended June 30, 2007 as compared to approximately $2.4 million for the sameperiod in the prior year and increased 49% to approximately $6.2 million for the six-month periodended June 30, 2007 as compared to $4.2 million for the same period in the prior year. Theincrease in R&D expenses for the three-month period ended June 30, 2007 as compared to the sameperiod in the prior year is primarily due to an increase of $756,000 in clinical activities, anincrease in preclinical activities of $246,000 and an increase in personnel costs of $79,000,partially offset by a decrease in manufacturing activities of $316,000. The increase in R&Dexpenses for the six-month period ended June 30, 2007 as compared to the same period in the prioryear is primarily due to an increase of $1.3 million in clinical activities, an increase inpreclinical activities of $375,000, an increase in personnel costs of $160,000, an increase innon-cash stock compensation expense of $75,000 and an increase in patent expenses of $70,000.     General and administrative expenses decreased 9% to $609,000 for the three-month period endedJune 30, 2007 as compared to $666,000 for the same period in the prior year and increased 21% toapproximately $1.5 million for the six-month period ended June 30, 2007 as compared to $1.3 millionfor the same period in the prior year. The decrease in expenses for the three-month period endedJune 30, 2007 as compared to the same period in the prior year is primarily due to a decrease ininvestor relations costs of $71,000. The increase in expenses for the six-month period ended June30, 2007 as compared to the same period in the prior year is primarily due to increases inpersonnel costs, strategic administrative fees and professional services totaling $191,000 and anincrease in non-cash stock compensation expense of $60,000.*- more -*
 

 
     Net loss for the three-month period ended June 30, 2007, was ($3.4) million or ($0.26) pershare as compared to a net loss of ($2.9) million or ($0.28) per share for the same period in theprior year. The net loss for the six-month period ended June 30, 2007 was ($7.0) million or($0.57) per share as compared to a net loss of ($5.1) million or ($0.50) per share for the sameperiod in the prior year. The increase in loss per share for the three-month and six-month periodsended June 30, 2007 was primarily due to increased spending in our clinical and preclinical productdevelopment programs.     As of June 30, 2007, Repros had cash, cash equivalents and marketable securities ofapproximately $31.8 million as compared to $6.7 million at December 31, 2006 and had 12,774,904shares of common stock outstanding on June 30, 2007.**Recent Corporate Activities** **•** July 2007, announced endometrial biopsy findings from our three-month U.S. Phase 2 andsix-month European Phase 1/2 studies of ProellexTM in the treatment of uterine fibroids andendometriosis, respectively. The results demonstrated that patients treated with Proellexhad a benign endometrium, a finding supporting the drug’s safety.  **•** June 2007, announced top-line data from our six-month European Phase 1/2 study whichindicated that Proellex demonstrated superior efficacy and safety when compared to thepharmaceutical standard of care in the treatment of endometriosis.  **•** June 2007, announced top-line results from our six-month U.S. non-pivotal Phase 3 studyof AndroxalTM. This trial demonstrated statistically significant increases in testosteronelevels versus placebo, without suppression of luteinizing hormone (“LH”) andnon-inferiority on all measured outcomes to Androgel®, the leading FDA approved therapy.  **•** April 2007, announced final top-line results from our three-month U.S. Phase 2 study ofProellexTM for the treatment of uterine fibroids. This study demonstrated that treatmentwith Proellex resulted in a statistically highly significant improvement in symptomsassociated with uterine fibroids and was generally well tolerated.**About Repros Therapeutics**     Repros is engaged in the development of pharmaceutical products that address conditions of themale and female reproductive systems. Proellex, the Company’s lead compound, is a selectiveblocker of the progesterone receptor which is being developed as an oral treatment for both uterinefibroids and endometriosis. Uterine fibroids affect numerous women of childbearing age in the U.S.and results in a significant number of hysterectomies each year. Endometriosis is a condition thataffects approximately 5.5 million women in the U.S. and Canada.     Repros recently completed a three-month U.S. Phase 2 clinical trial of Proellex for thetreatment of symptoms associated with uterine fibroids and patients from this study have beenenrolled into a one-year open-label safety study. We intend to initiate a pivotal Phase 3 study byyear end 2007 and anticipate a potential NDA filing for this indication at the end of 2008. Reprosalso recently completed a Proellex six-month European Phase 1/2 clinical trial for the treatment ofsymptoms associated with endometriosis, and intends to initiate a U.S. Phase 2 study in thethird quarter of 2007 for this indication.*- more -*
 

 
     Androxal, the Company’s other product candidate in late clinical development, is designed torestore normal testosterone production by the testes in patients suffering from secondaryhypogonadism. According to the Urology Channel, recent estimates show that approximately 13million men in the United States experience testosterone deficiency. Repros recently completed anAndroxal non-pivotal six-month U.S. Phase 3 clinical trial and is enrolling patients from thistrial into a one-year open-label safety study. We intend to initiate our first U.S. pivotal Phase3 clinical trial in the fourth quarter of 2007.     For more information, please visit the Company’s website at http://www.reprosrx.com.     *Any statements that are not historical facts contained in this release are forward-lookingstatements that involve risks and uncertainties, including Repros’ ability to have success in theclinical development of its technologies, the timing of enrollment and release of data in suchclinical studies and the accuracy of such studies, limited patient populations of clinical studiesto date and the possibility that final data may not be consistent with interim data, Repros’ability to raise additional capital in a timely manner and on acceptable terms or at all and suchother risks which are identified in the Company’s Annual Report on**Form 10-K**for the year endedDecember 31, 2006 and Repros’ Quarterly Report on**Form 10-Q**for the quarter ended March 31, 2007,as they may be updated by the Company’s Exchange Act filings from time to time. These documents areavailable on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention orobligation to update or revise any forward-looking statements, whether as a result of newinformation, future events or otherwise.*                  *- more -*
 

 
**REPROS THERAPEUTICS INC. AND SUBSIDIARY**